To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
ProJect Pharmaceutics and TUM-Spin-off ImevaX Announce Agreement
IMX101 is a multicomponent vaccine, making the formulation development particularly challenging.
The contract covers activities in developing a rational formulation based on ProJect Pharmaceutics´ Predictive Formulation Analytics. This technology offers an innovative scientific approach for designing optimized protein formulations by determining the most favorable composition for the native structure of the protein with regard to its intra- and intermolecular physicochemical properties. By analyzing the response to certain excipients the most promising formulation candidates can be identified quickly and reliably reducing the need for extensive stability testing.
Promising formulation candidates have successfully been evaluated and are continuously optimized within the development program since its launch in mid 2013.
Financial terms of the current agreement are not disclosed.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
